SEC Form 4 · accession 0001581754-26-000006
Latigo Biotherapeutics, Inc. · LTGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James B. Tananbaum
Director · 10% Owner
Period of report
Aug 10, 2026
Accepted (ET)
Aug 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002056611
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 10, 2026 | C | 3,117,664 | — | A | 3,117,664 | I | See footnote |
| Common StockF1,F2 | Aug 10, 2026 | C | 445,320 | — | A | 3,562,984 | I | See footnote |
| Common StockF1,F3 | Aug 10, 2026 | C | 1,125,823 | — | A | 1,125,823 | I | See footnote |
| Common StockF1,F3 | Aug 10, 2026 | C | 742,201 | — | A | 1,868,024 | I | See footnote |
| Common StockF3 | Aug 10, 2026 | P | 140,000 | $18.00 | A | 2,008,024 | I | See footnote |
| Common StockF4,F3 | Aug 10, 2026 | C | 195,776 | — | A | 2,203,800 | I | See footnote |
| Common StockF1,F5 | Aug 10, 2026 | C | 3,117,664 | — | A | 3,117,664 | I | See footnote |
| Common StockF1,F5 | Aug 10, 2026 | C | 296,880 | — | A | 3,414,544 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A-2 Convertible StockF1,F2 | — | Aug 10, 2026 | C | 3,117,664 | D | — | — | Common Stock | 3,117,664 | 0 | I |
| Series B Convertible Preferred StockF1,F2 | — | Aug 10, 2026 | C | 445,320 | D | — | — | Common Stock | 445,320 | 0 | I |
| Series A-2 Convertible Preferred StockF1,F3 | — | Aug 10, 2026 | C | 1,125,823 | D | — | — | Common Stock | 1,125,823 | 0 | I |
| Series B Convertible Preferred StockF1,F3 | — | Aug 10, 2026 | C | 742,201 | D | — | — | Common Stock | 742,201 | 0 | I |
| Series A-2 Convertible Preferred StockF1,F5 | — | Aug 10, 2026 | C | 3,117,664 | D | — | — | Common Stock | 3,117,664 | 0 | I |
| Series B Convertible Preferred StockF1,F5 | — | Aug 10, 2026 | C | 296,880 | D | — | — | Common Stock | 296,880 | 0 | I |
| Convertible Promissory NoteF4,F3 | — | Aug 10, 2026 | C | 195,776 | D | — | — | Common Stock | 195,776 | 0 | I |
Explanation of responses
- F1Each share of preferred stock converted automatically into 1 share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The preferred stock had no expiration date.
- F2The securities are held of record by Foresite Capital Fund V, L.P. (Fund V). Foresite Capital Management V, LLC (FCM V) is the general partner of Fund V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. The Reporting Person is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over the securities held by Fund V. Each of Fund V, FCM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- F3The securities are held of record by Foresite Capital Fund VI, LP (Fund VI). Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. The Reporting Person is the sole managing member of FCM VI and may be deemed to have sole voting and dispositive power over the securities held by Fund VI. Each of Fund VI, FCM VI and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- F4Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.
- F5The securities are held of record by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V). Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over the shares held by Opportunity Fund V. The Reporting Person is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over the securities held by Opportunity Fund V. Each of Opportunity Fund V, FCOM V and the Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.